RVTY

Rating neutralAI Memo

Revvity

As of 2026-05-28/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 beat and FY26 outlook update • 2026-05-05

Expected move: +6%

Biggest risk

Margin compression, a lower FY26 pro forma EPS guide, and execution/regulatory risk around the China divestiture can cap the multiple. If research end markets stay uneven, the stock may trade more on estimate revisions than on the one-time portfolio move.

Invalidation

Break below $86 or thesis failure.

What would change my mind?

The quarter beat on revenue and adjusted EPS, diagnostics growth stayed solid, and the China divestiture could improve portfolio quality and mix. The available sell-side target set still sits above the stock, so there is room for a rerate if execution holds.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-28

Base target

$111

p=50%

Bull target

$126

p=20%

Bear target

$86

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

The quarter beat on revenue and adjusted EPS, diagnostics growth stayed solid, and the China divestiture could improve portfolio quality and mix.
The available sell-side target set still sits above the stock, so there is room for a rerate if execution holds.
At $96.79, RVTY trades about 22% below the median analyst target of $117.88, but the near-term guide reset and margin pressure make that upside less clean than the headline target gap suggests.

BearKey bullets

Adjusted operating margin fell to 23.6% in Q1 from 25.6% a year ago, so operating leverage is not yet fully recovered [#8-K-2026-05-05].
FY26 pro forma adjusted EPS guidance of $5.20-$5.30 leaves less room for upside than a fresh rerating would require [#8-K-2026-05-05].
The China Immunodiagnostics divestiture still needs a definitive agreement and regulatory approvals, so timing and proceeds are uncertain [#8-K-2026-05-05].

WatchKey bullets

Q1 beat and FY26 outlook update

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $111 (p=50%)

Bull/Bear spread: +21% / -18%

Vs latest close: Bull +21% · Base +6% · Bear -18%

Scenario probabilities

Bull Target: $126 (p=20%)Base Target: $111 (p=50%)Bear Target: $86 (p=30%)

Commentary

The immediate reaction was mildly positive in the available news context, but the tone stays mixed because investors also had to digest the lower FY26 pro forma EPS guide and margin compression. Analyst-revision evidence is limited rather than decisively bullish, so this remains a cautious monitoring setup around the Q2 2026 divestiture agreement checkpoint and subsequent 2027 regulatory close path.

As of 2026-05-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

The quarter beat on revenue and adjusted EPS, diagnostics growth stayed solid, and the China divestiture could improve portfolio quality and mix.
The available sell-side target set still sits above the stock, so there is room for a rerate if execution holds.

Scenarios

Bull Target (Scenario probability)

$126 / p=20% prob

Base Target (Scenario probability)

$111 / p=50% prob

Bear Target (Scenario probability)

$86 / p=30% prob

Price $105 as of 2026-05-29

Nearest Scenario: Base (∆ 6%)

Targets vs latest close: Bull +21% · Base +6% · Bear -18%

Sentiment & Exposure

News Sentiment (30d)

0.12

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-05
Q1 beat and FY26 outlook update
Revvity reported Q1 revenue of $711 million and adjusted EPS of $1.06, with pro forma revenue of $687 million and pro forma adjusted EPS of $1.04; management also guided FY26 pro forma revenue to $2.81-$2.84 billion and pro forma adjusted EPS to $5.20-$5.30 [#8-K-2026-05-05].
Prob 85.00% • Move 3.00% • Priced-in 70.00%
EVENT2026-06-30
Q2 2026 China Immunodiagnostics definitive-agreement checkpoint
Revvity said it entered a letter of intent to divest its China Immunodiagnostics business, which represented about 6% of FY2025 revenue, and expects a definitive agreement to be signed in the second quarter of 2026; closing is expected in 2027 after required regulatory approvals [#8-K-2026-05-05].
Prob 60.00% • Move 4.00% • Priced-in 35.00%

Risks

Adjusted operating margin fell to 23.6% in Q1 from 25.6% a year ago, so operating leverage is not yet fully recovered [#8-K-2026-05-05].
FY26 pro forma adjusted EPS guidance of $5.20-$5.30 leaves less room for upside than a fresh rerating would require [#8-K-2026-05-05].
The China Immunodiagnostics divestiture still needs a definitive agreement and regulatory approvals, so timing and proceeds are uncertain [#8-K-2026-05-05].

Peers

Symbol	Summary
BMRN	More comparable mid-cap profitable biotech/life-science name; useful as a valuation and margin-quality reference, though its product mix is different.
GILD	Large-cap cash-generative biopharma peer that helps frame quality and multiple support, but it is much more mature than RVTY.
ARWR	Higher-beta biotech peer that highlights how the market prices growth and optionality versus steady execution.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-28

AI Stock Memo: RVTY - Revvity - RankAlpha